Differential 18F-FDG and 18F-FLT uptake on serial PET/CT imaging before and during definitive chemoradiation for non-small cell lung cancer

Journal of Nuclear Medicine

Volumn 55, Issue 7, 2014, Pages 1069-1074

  Everitt, Sarah J ^a,b,c   Ball, David L ^a,c   Hicks, Rodney J ^a,c   Callahan, Jason ^a,b   Plumridge, Nikki ^a   Collins, Marnie ^a   Herschtal, Alan ^a   Binns, David ^a   Kron, Tomas ^a,b,c   Schneider, Michal ^b   MacManus, Michael ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Non small cell lung cancer; Positron emission tomography; Radiation therapy

Indexed keywords

3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE;

ADULT; AGED; ARTICLE; BIOLOGICAL ACTIVITY; BRAIN METASTASIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL METABOLISM; CELL PROLIFERATION; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; MULTIMODAL IMAGING; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PRIMARY TUMOR; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; DRUG EFFECTS; FOLLOW UP; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIATION RESPONSE; SURVIVAL; TRANSPORT AT THE CELLULAR LEVEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CHEMORADIOTHERAPY; DIDEOXYNUCLEOSIDES; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84904097592     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.131631     Document Type: Article

References (22)

1. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500-2507. (Pubitemid 36706537)
2. MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol. 2009;91:85-94.
3. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med. 2009;50:88-99.
4. Mac Manus M, Hicks RJ, Matthews J, Wirth A, Rischin D, Ball D. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for nonsmall cell lung cancer correlates with patterns of failure. Lung Cancer. 2005;49:95-108. (Pubitemid 40798098)
5. van Baardwijk A, Bosmans G, Dekker A, et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy: a prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol. 2007;82:145-152.
6. 18fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother Oncol. 2011;98:109-116.
7. Feng M, Kong FM, Gross M, Fernando S, Hayman JA, Ten Haken RK. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys. 2009;73:1228-1234.
8. Gillham C, Zips D, Ponisch F, et al. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning? Radiother Oncol. 2008;88:335-341.
9. 18F] fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol. 2007;25:3116-3123.
10. Kenny LM, Aboagye EO, Price PM. Positron emission tomography imaging of cell proliferation in oncology. Clin Oncol (R Coll Radiol). 2004;16:176-185. (Pubitemid 38559685)
11. 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;75:1098-1104.
12. Bayne M, Hicks RJ, Everitt S, et al. Reproducibility of "intelligent" contouring of gross tumor volume in non-small-cell lung cancer on PET/CT images using a standardized visual method. Int J Radiat Oncol Biol Phys. 2010;77:1151-1157.
13. 18F-FDG PET/CT in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2010;37:1291-1299.
14. 18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer. Cancer. 2010;116:4095-4102.
15. 18F-FDG. J Nucl Med. 2003;44:1426-1431.
16. 18F-3′- fluoro-3′-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? J Nucl Med. 2004;45:1677-1682.
17. 18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
18. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726-735.
19. 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34:1610-1616.
20. Kong FM, Ten Haken R, Gross M, et al. FDG-PET/CT during radiation therapy to predict survival and guide individualized adaptive dose escalation in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;75(3, suppl 1):S35-S36.
21. 18F- fluorothymidine PET. J Nucl Med. 2011;52:1871-1877.
22. 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res. 2011;17:3304-3315.